Attachment B

Form Approved OMB No. 0925-0002 Exp. Date 08/31/2015

NIH- COMMERCIALIZATION ASSISTANCE PROGRAM (CAP) 2012/2013 Accelerated Commercialization Track (ACT)

COMMERCIALIZATION PROGRESS TRACKING FORM- Baseline

(November 2012 and August 2013)

PLEASE SUBMIT BY MM/DD/YYYY

Comp	pany	Name:	,
------	------	-------	---

If company name has changed since your participation in CAP, please provide it here:

CAP SBIR/STTR Grant or Contract #:

Is the technology	supported b	y the	above	SBIR/STTR	Grant or	Contract	still	active	with	the
company's comme	rcialization e	fforts?	Ye	esNo						

The tracking form is divided into four sections: (1) Road-to-the-Deal activities, (2) Funding, (3) Revenue, (4) and Other success indicators (employees, acquisitions). It not only provides you the opportunity to report your measurable achievements, but it also allows for your opinions regarding the impact CAP may have had on your progress.

IMPORTANT: NOTE ON CAP IMPACT

When assessing the CAP impact on partnership activities, funding, and revenue, please consider both the direct and indirect impacts of the program. For example, a direct impact would include introducing you to a potential partner and an indirect impact would include the tools and training delivered by CAP that may have significantly contributed, or in your opinion, would significantly contribute to, the development of a partnership. Thus, "Major Impact" would indicate that CAP significantly influenced the company's growth whether it be a result that is tangible (a "deal") or intangible (being better prepared and oriented toward a potential outcome). "Valuable Impact" would indicate that CAP contributed to your growth (tangible or intangible) but the impact was less than "Major." It is understood that these differences are subjective in nature. However, in either case your assessment as to whether you are "better off" after CAP than you were before you entered the program is what is being sought. "Little or No Impact" is self-explanatory.

Public reporting burden for this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0627). Do not return the completed form to this address.

ROAD-TO-THE-DEAL ACTIVITIES	5		
Are you currently seeking partnerships? Yes No (If No, please skip part b and proceed to answer part c)			
What kind of partnerships are you considering? (Check one or more, as appropriate): Strategic Partner Technical collaboration Distribution Other (Please specify)			
though you have already stated Yes or N ged in any partnership-related activities l -related technology. Please only state no	between November 1, 2012 and Au	gust 31, 2013 with regards to	
Activity	Number of road-to-the-deal activities in which your company has engaged during your participation in CAP	Describe Significant Outcomes	
Contacts with Partners Count only contacts with whom you had a meaningful conversation with			
about your mutual interests			
Meetings with Partners Meetings can be face-to-face or by phone/web but should involve exploration of potential deals in some			
detail. Confidential Disclosure			
Agreements signed CDA (NDA) agreements are generally a pre-requisite for any serious discussion with potential			
Negotiations with Partners At this stage, all parties are interested in the deal and you are exploring			
various give and take scenarios.			
Initial Proposals and Term Sheets These are proposals of key terms of the deal and serve as the basis for a final agreement.			
Deals			
Signed legal documents committing partners to a process, timeframe and outcome. If appropriate to the "deal(s)", please indicate the dollar amount(s) involved.			

Deals		
Signed legal documents committing		
partners to a process, timeframe and		
outcome. If appropriate to the		
"deal(s)", please indicate the dollar		
amount(s) involved.		
Please indicate the level of impact of the	CAP on your partnership-related	activities for the period November 1,
2012 and August 31, 2013. (Note: Pleas	se refer to the CAP Impact guideli	ne on the page 1.)
	_	
Major Impact Valuable Im	pact Little or No Impact	t
Comments:		
Comments.		

a)	Are you cu	re you currently seeking outside financing? Yes No (If No, please skip part b and proceed to answer part c)						
b)	If yes, please check each of the following as appropriate to your situation:							
e aı		t (If check, please complete parts c and d only) n or Other/Alternative Financing (e.g. receivable financing; p	lease specify) (If check, plea	se complete part				
am	ount of fund	ou have already stated Yes or No to currently seeking outsiding, if any, received by your company including your CAP-r 2012 and August 31, 2013. Please only state numbers and not	elated technology in the tin	ne period				
		Investor Party Amount of Equity Investment						
		Friends and Family						
		Angels High net worth individuals; always invest as individuals although may belong to angel organizations.						
		Venture Capitalists (VCs) Institutional investors						
		Strategic Investors Investors that are looking to achieve other goals in addition to financial returns; typically, this may include corporations seeking to fill or expand their product lines or corporate "venture arms."						
d)	Please indicate the level of impact of the CAP on funding received for the period November 1, 2012 and August 31, 2013. (Note: Please refer to the CAP Impact guideline on the first page.) Major Impact Valuable Impact Little or No Impact							
	Comments	·						
e) Although you have already stated Yes or No to currently seeking outside financing, please state the total a of Bank Loan/Other Financing, if any, received by your company including your CAP-related technology time period November 1, 2012 and August 31, 2013. Please only state numbers and not qualitative data.								
		Bank Loan/Other	Amount of Financing					
		Bank Loan Financial Institution, include banks and credit unions.						
		Other/Alternative Financing (e.g. receivable financing); please specify:						
f)	November	dicate the level of impact of the CAP on "Bank Loan" or "Other/Alternative Financing" for the period er 1, 2012 and August 31, 2013. (Note: Please refer to the CAP Impact guideline on the first page.)						
		Major Impact Valuable Impact Little or No Impact						
	Comments	·						

3. REVENUE

PI	Please report information for your company and not just your CAP-related technology.				
a)	Indicate your company's largest source of revenue in the past 10 months (November 1, 2012 and August 31, 2013) (<i>Choose one only</i>)				
	R&D Grant/Contracts Products o	or Services	Licensing Fees a	and Royalties	
b)	What is the dollar range of your company's <u>c</u> (November 1, 2012 and August 31, 2013)?	umulative sa	ales of products/service	es for the past 10 r	nonths
	No sales yet Less than \$50,000 \$50,000 - \$99,999 \$100,000 - \$499,999	\$1,00 \$5,00	,000 - \$999,999 00,000 - \$4,999,999 00,000 - \$9,999,999 000,000 and above, plo	ease specify \$	
c)	Please indicate the level of impact of the CAF August 31, 2013. (Note: Please refer to the C				er 1, 2012 and
	Major Impact Valuable Impact	Li	ttle or No Impact		
	Comments:				
4. a)	 4. OTHER SUCCESS INDICATORS (EMPLOYEES, ACQUISITIONS) a) Have the number of employees in your company increased since November 2012? Yes No If yes, please specify the number of employees in November 2012, versus the current number of employees, and the titles/positions of the new employees in the table below. Count part-time employees as 1 (i.e. do not use fractional numbers to count part-time employees.) 				
		Employee	Information	Titles/Positions	
	Number of Employees in November 2012				
	Current Number of Employees				
b)	b) If you had an increase in employment, 1) Was it due to obtaining additional SBIR funds? Yes No 2) Did CAP influence your ability to hire? Yes No				
c)	Has your company been acquired?		Yes	No	
d)	Are you currently in discussion regarding an a 1) Has your company been acquired?	acquisition?	Yes Yes		
	If your answer to either of the above in c) is "Yes", NIH would like to continue tracking the progress of the SBIR-developed technology. Please provide the following information.				
			Acquisition Informa	ation	1
			1		i

Name of the Acquiring Company	
Change in Company Name as a Result of the Acquisition	
Change in Company Contact Information as a Result of the Acquisition	
Additional Details	

THANK YOU ONCE AGAIN FOR YOUR PARTICIPATION IN THE 2012/2013 CAP AND FOR YOUR TIME IN PROVIDING THIS VALUABLE FEEDBACK. IT WAS AN HONOR TO WORK WITH YOU AND WE WISH YOU THE BEST OF SUCCESS.